Catalent Expert to Discuss Supply Strategies at Upcoming Clinical Outsourcing Group Conference
SOMERSET, N.J. – February 16, 2023 — Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that its Global Director of Clinical Supply Management, Stephanie Graham, is to speak at the upcoming Clinical Outsourcing Group (COG) Conference, to be held at the Royal Garden Hotel, London, U.K., on Feb. 21-22, 2023.
Ms. Graham’s presentation, on Feb. 22 at 10:30 a.m., entitled “Proactive Strategies to Evaluate and Mitigate Clinical Supply Risk,” focuses on strategies that build understanding of risk assessment within clinical supply planning, and how studies’ protocol requirements, drug characteristics, packaging specifications, and patient compliance concerns, must be identified and addressed in order to mitigate risk for successful clinical supply outcomes.
In her role at Catalent, Stephanie Graham has responsibility for clinical supply within the European, Asia-Pacific and North American regions. She has over 17 years of experience in the industry, with specific focus on forecasting, packaging and distribution of clinical materials. Prior to joining Catalent, she worked at Shire Pharmaceuticals, Takeda and Fisher Clinical Services, and before working in the pharmaceutical industry, spent 13 years in international shipping. She is a member of the Global Clinical Supplies Group (GCSG) and Clinical Supplies Discussion Group (CSDG).
With a network spanning the U.S., U.K., Germany, Singapore, Japan, and China, plus more than 50 additional global depots, Catalent’s clinical supply services can handle a broad range of international compliance and distribution requirements to support global clinical trials.
To find out more information about this event, visit www.catalent.com/events/cog-uk-2023
NOTES FOR EDITORS
ABOUT CATALENT CLINICAL SUPPLY SERVICES
Catalent solves today’s clinical trial challenges and develops innovative solutions for the future. The company’s commitment to quality and service excellence is evident in its flexible solutions, modern global facilities, and over 25 years’ experience of reliably supplying thousands of studies of all sizes and complexities, all around the world.
Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.
Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.
Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit